EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis

Ahmed B Bayoumy iD, Hedwig M A D'Agnolo, Nanne K H de Boer, Chris J J Mulder, Luc J J Derijks

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Ahmed B Bayoumy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Thioguanine, Allopurinol, Inflammatory Bowel Diseases, Mercaptopurine. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Shunting (hypermethylating) thiopurine metabolism, characterized by excessive 6‐MMPR production and (sub)therapeutic 6‐TGN levels, poses a significant challenge in the treatment of inflammatory bowel disease (IBD). This study evaluates the metabolic outcomes of switching to low‐dose thiopurine with allopurinol (LDTA) or thioguanine (TG) in IBD patients with shunting metabolism.

Methods

This retrospective study analysed demographic data, thiopurine metabolite profiles, and adverse event rates in shunting IBD patients before and after switching to LDTA or TG therapy. Metabolite variability was assessed by examining alterations in 6‐MMPR and 6‐TGN levels and their correlation before and after therapy switch.

Results

Both therapies significantly reduced toxic 6‐MMPR levels, with 100% of patients achieving non‐toxic levels (6‐MMPR‐level below 7000 pmol/8 × 10E8 RBC) post‐therapy. For TG, 93% of patients attained non‐toxic 6‐TGN levels (6‐TGN < 1000 pmol/8 × 10E8 RBC). In contrast, LDTA showed greater variability in 6‐TGN outcomes, with 50% of patients reaching therapeutic levels, 31% remaining subtherapeutic, and 19% within toxic range. The slope for LDTA was significantly positive (1.044, R 2 = 0.4515, P = 0.004), reflecting proportional increases in 6‐TGN levels.

Conclusions

Switching to LDTA or TG therapy in shunting IBD patients resulted in favourable alterations in thiopurine metabolism. However, LDTA appears to have a slightly less favourable metabolite profile, with some residual 6‐MMPR formation and fewer patients achieving normal 6‐TGN levels compared to TG. Given the challenges associated with achieving optimal thiopurine metabolite levels with LDTA and the need for closer monitoring of 6‐TGN levels, TG appears a more suitable option for thiopurine shunting IBD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThioguanineAllopurinolInflammatory Bowel DiseasesMercaptopurineAzathioprineHumansRetrospective StudiesFemaleMaleAdultMiddle AgedYoung AdultDrug SubstitutionGuanine NucleotidesAgedThionucleotidesMethyltransferasesThioinosine

Stichwörter der Autor:innen

allopurinolhypermethylationinflammatory bowel diseasethioguaninethiopurine shuntingthiopurines

Substanzen

ThioguanineAllopurinolMercaptopurineGuanine NucleotidesAzathioprine6-thioguanylic acidThionucleotidesMethyltransferases6-methylthiopurine ribonucleoside-5'-phosphateThioinosine

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, Máxima Medical Center, Veldhoven, The Netherlands.
  • Department of Gastroenterology and Hepatology, Máxima Medical Center, Veldhoven, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology and NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.

ORCID-Profile: Ahmed B Bayoumy

Zitieren

APA

Bayoumy, A. B., D'Agnolo, H. M. A., de Boer, N. K. H., Mulder, C. J. J., & Derijks, L. J. J. (2025). The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70112

Vancouver

Bayoumy AB, D'Agnolo HMA, de Boer NKH, Mulder CJJ, Derijks LJJ. The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70112

BibTeX
@article{Bayoumy2025,
  author = {Bayoumy, Ahmed B and D'Agnolo, Hedwig M A and de Boer, Nanne K H and Mulder, Chris J J and Derijks, Luc J J},
  title = {The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70112}
}
Kostenlos starten →